News
GRAL
16.51
+0.76%
0.13
Grail tests first patient for TROPION-Lung12 Phase 3 study
TipRanks · 5d ago
GRAIL ANNOUNCES FIRST PATIENT TESTED WITH BLOOD-BASED ASSAY IN GLOBAL PHASE 3 ADJUVANT LUNG CANCER STUDY
Reuters · 5d ago
Weekly Report: what happened at GRAL last week (1111-1115)?
Weekly Report · 5d ago
Wolfe starts Grail at Peer Perform on time and money needs
TipRanks · 11/15 11:11
GRAIL 13G Filing Shows Sessa Capital (Master), L.P. Reported A 9.66% Stake In The Co As Of September 30, 2024
Benzinga · 11/14 20:40
SESSA CAPITAL (MASTER), L.P. REPORTS 9.66% PASSIVE STAKE IN GRAIL AS OF SEPT 30 - SEC FILING
Reuters · 11/14 20:38
GRAIL, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/14 00:03
*Grail 3Q Loss/Shr $3.94 >GRAL
Dow Jones · 11/12 22:15
*Grail 3Q Rev $28.7M >GRAL
Dow Jones · 11/12 22:15
GRAIL GAAP EPS of -$3.94, revenue of $28.65M misses by $5.25M
Seeking Alpha · 11/12 21:38
GRAIL Q3 EPS $(3.94) Up From $(28.71) YoY, Sales $28.65M Up From $20.72M YoY
Benzinga · 11/12 21:12
GRAIL INC: CASH BALANCE OF $853.6 MLN PROVIDES RUNWAY INTO 2028
Reuters · 11/12 21:06
GRAIL INC - QTRLY LOSS PER SHARE $3.94
Reuters · 11/12 21:02
GRAIL INC - CASH BALANCE OF $853.6 MILLION PROVIDES RUNWAY INTO 2028
Reuters · 11/12 21:02
Weekly Report: what happened at GRAL last week (1104-1108)?
Weekly Report · 11/11 12:50
Weekly Report: what happened at GRAL last week (1028-1101)?
Weekly Report · 11/04 12:44
Weekly Report: what happened at GRAL last week (1021-1025)?
Weekly Report · 10/28 12:32
GRAIL Presents Early Results From REFLECTION Real-World Evidence Study; Says Veteran Cohort Had Cancer Signal Detection Rate Consistent With Other Populations That Received MCED Test
Benzinga · 10/23 22:06
More
Webull provides a variety of real-time GRAL stock news. You can receive the latest news about Grail Inc through multiple platforms. This information may help you make smarter investment decisions.
About GRAL
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.